AE Preferred Term, % (n) | Dose-Optimization Phase (Safety Population) |
---|---|
 | LDX-All Doses (n = 142) a |
Any TEAE | 79.6 (113) |
Anxiety | 5.6 (8) |
Decreased appetite | 36.6 (52) |
Dry mouth | 30.3 (43) |
Fatigue | 4.9 (7) |
Feeling jittery | 5.6 (8) |
Headache | 19.7 (28) |
Insomnia | 18.3 (26) |
Irritability | 8.5 (12) |
Nausea | 7.7 (11) |
Upper respiratory tract infection | 9.9 (14) |